Flurry of announcements from Agenix last week included...

Flurry of announcements from Agenix last week included revelation that its secret product candidate AGX-1009 uses the same active ingredient as “Viread”, “Tenofovir”. A Google is interesting. “Viread is a once a day integrase inhibitor”. This article on a hepatitis B website ( http://www.hivandhepatitis.com/2010_conference/aasld/docs/1123_b.html ) said “Tenofovir suppressed HBV replication in most [nucleoside/nucleotide]-naive and [nucleoside/nucleotide]-experienced or resistant patients in field practice,” the investigators concluded. “Few patients showed an impaired renal and tubular function of multifactorial origin.” According to a 2009 article in Forbes (http://www.forbes.com/2009/03/23/hiv-aids-gilead-business-health-care-viread.html ), “Viread now generates an annual $621 million” for a company called Gilead Sciences Inc. Also says Gliead has also got a “combo” pill that includes Tenofovir that brings in $2.1 billion. Doesn’t look like they are selling either in China yet. AGX stock down .001 since 2008 so AGX-1009 is not priced in despite possible blockbuster potential. Early to assess but looks too impressive to not be priced in soon.